Abstract
Targeted therapies have unique roles in the management of genitourinary cancers. To date, many biomarkers which are directly involved in the pathways of action of these agents have not proven effective. Most recently, an immunotherapy agent was approved by the FDA for the treatment of metastatic urothelial cancer, with PD-L1 expression as its predictive marker of response. Newer markers which show promise are those identified by molecular techniques such as genotyping or next-generation sequencing of either tumor tissue or circulating tumor cells/DNA. This sophisticated precision medicine strategy shows promise in identifying novel predictors of patient response to targeted therapies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Konda B, Kirschner LS. Novel targeted therapies in adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2016;23(3):233–41. https://doi.org/10.1097/MED.0000000000000247.
Millis SZ, Ejadi S, Demeure M. Molecular profiling of refractory adrenocortical cancers and predictive biomarkers to therapy. J Biomark Cancer. 2015;7:69–76. https://doi.org/10.4137/BIC.S34292. eCollection 2015.
Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65(4):765–73.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
Zhang T, Zhu J, George DJ, Nixon AB. Metastatic clear cell renal cell carcinoma: circulating biomarkers to guide antiangiogenic and immune therapies. Urol Oncol. 2016;34(11):510–8. https://doi.org/10.1016/j.urolonc.2016.06.020.
Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, et al. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017;7:41371. https://doi.org/10.1038/srep41371.
García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, et al. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight. 2016;1(10):e86051.
Escudier B, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–68.
Rini BI, McDermott DF, Hammers H, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81.
Jones RT, Felsenstein KM, Theodorescu D.Pharmacogenomics: biomarker-directed therapy for bladder cancer. Urol Clin N Am. 2016;43(1):77–86. https://doi.org/10.1016/j.ucl.2015.08.007.
Bellmunt J, et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii40–8.
Contreras-Sanz A, Roberts ME, Seiler R, Black PC. Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. Int J Urol. 2017;24(1):7–15. https://doi.org/10.1111/iju.13193.
Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–47. https://doi.org/10.1016/j.juro.2015.06.106.
Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics. Eur Urol. 2017;71(2):237–46. https://doi.org/10.1016/j.eururo.2016.08.024.
Miyamoto DT, Lee RJ. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: tools for real-time precision medicine? Urol Oncol. 2016;34(11):490–501. https://doi.org/10.1016/j.urolonc.2016.09.001.
McNeel DG, Bander NH, Beer TM, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016;4:92.
Fankhauser CD, Honecker F, Beyer J, Bode PK. Emerging therapeutic targets for male germ cell tumors. Curr Oncol Rep. 2015;17(12):54. https://doi.org/10.1007/s11912-015-0479-4.
Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C. Investigational targeted therapies for the treatment of testicular germ cell tumors. Expert Opin Investig Drugs. 2016;25(9):1033–43. https://doi.org/10.1080/13543784.2016.1195808.
McDaniel AS, Hovelson DH, Cani AK, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 2015;75(24):5219–27. https://doi.org/10.1158/0008-5472.CAN-15-1004.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Khor, L.Y., Tan, P.H. (2019). Predictive Biomarkers and Targeted Therapies in Genitourinary Cancers. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_37
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)